Future Of British Business
AstraZeneca Looks to More Than Double New Cancer Drugs by 2030
- UK’s biggest drugmaker aims for top spot in cancer market
- Astra needs to unseat Bristol, Roche to be oncology leader
This article is for subscribers only.
AstraZeneca Plc is aiming to more than double its portfolio of new cancer drugs by the end of this decade, seeking the top spot in the world’s most lucrative category of medicines.
The UK drugmaker has added seven new cancer medicines since 2014, after Chief Executive Officer Pascal Soriot made a risky bet on an oncology pipeline to revive growth and ward off a hostile takeover from Pfizer Inc. Now, with blockbuster treatments for malignancies in the lungs, ovaries and blood, AstraZeneca aspires to be the fastest-growing maker of cancer drugs, oncology chief Dave Fredrickson said at Europe’s biggest cancer conference on Friday.